Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.33

-0.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: greedsgd_2000 who wrote (1636)	9/15/2000 9:44:58 AM
From: tom pope	Read Replies (1) of 52153

NMPS: impressive results, especially if one thinks early detection is important: From PR newswire >>Blood specimens from seventy-eight women have been tested using Matritech's proprietary specimen preparation and mass spectrometry procedures. Forty-five of these specimens came from women diagnosed with breast cancer in various stages of the disease and 5 were from women with Ductal Carcinoma In Situ (DCIS), a condition that can progress to cancer. An additional 28 specimens came from women who had no breast disease or had been diagnosed as having benign breast disease. NMP66 was found in the blood of every woman who was diagnosed with cancer and was absent in all of the 'normal' specimens<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next